Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | UBE2I | P63279 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366004 | 0.75 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL4370979 | 0.75 | ADORA2A (0.77) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL4369863 | 0.74 | ADORA2A (0.72) | ADORA2AADORA1ADORA3ADORA2BLMNA | |
| SCHEMBL13668448 | 0.74 | ADORA2A (0.49) | ADORA2AADORA1ADORA3MAPTTSHR | |
| SCHEMBL4713838 | 0.69 | ADORA2A (0.65) | ADORA2AADORA1ADORA3MAPTTSHR | |
| SCHEMBL14002324 | 0.69 | ADORA3 (0.47) | ADORA2AADORA1ADORA3MAPTTSHR | |
| SCHEMBL29781287 | 0.65 | MAPT (0.68) | MAPTLMNAALOX15SMN1; SMN2HSD17B10 | |
| SCHEMBL20889707 | 0.65 | TRIM33 (0.68) | ADORA2AADORA1ADORA3MAPTTSHR | |
| SCHEMBL4369810 | 0.63 | ADORA2A (0.55) | ADORA2AADORA1ADORA3TSHRADORA2B | |
| SCHEMBL5459646 | 0.63 | ADORA2A (0.74) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598256-B2 | Parkinson's disease; antidepressants; cognition activators; attention deficit disorders; narcolepsy; N,N-dimethyl-4-(2-furyl)-1H-pyrrolo[2,3- d]pyrimidine-2-amine | VERNALIS RESEARCH LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598256-B2 | Parkinson's disease; antidepressants; cognition activators; attention deficit disorders; narcolepsy; N,N-dimethyl-4-(2-furyl)-1H-pyrrolo[2,3- d]pyrimidine-2-amine | VERNALIS RESEARCH LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| US-7598256-B2 | Parkinson's disease; antidepressants; cognition activators; attention deficit disorders; narcolepsy; N,N-dimethyl-4-(2-furyl)-1H-pyrrolo[2,3- d]pyrimidine-2-amine | VERNALIS RESEARCH LIMITED (GB) | 2009-10-06 | — | — | US | disclosed |
| EP-1363639-B1 | PYRROLO 2,3-d PYRIMIDINE AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-08-20 | — | — | EP | disclosed |
| US-7098333-B2 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2006-08-29 | — | — | US | disclosed |
| US-20060128731-A1 | Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-06-15 | — | — | US | disclosed |
| US-20040092537-A1 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128731-A1 | Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists | CHRNA6, CNR1, ADORA2A | ADORA2A 3/4885ADORA1 11/4885ADORA3 7/4885 |
| US-20040092537-A1 | Pyrrolo[2,3-d]pyrimidine and their use as purinergic receptor antagonists | CNR1, CNR2, CHRNA6 | ADORA2A 7/4885ADORA1 18/4885ADORA3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.